Premium
Combined use of external therapeutic ultrasound and tirofiban has synergistic therapeutic effects on no‐reflow after myocardial reperfusion
Author(s) -
Xu TingYan,
Zhao Hang,
Qiao ZhiQing,
He Ben,
Shen XueDong
Publication year - 2018
Publication title -
echocardiography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 62
eISSN - 1540-8175
pISSN - 0742-2822
DOI - 10.1111/echo.14049
Subject(s) - tirofiban , medicine , cardiology , myocardial infarction , ultrasound , anesthesia , pharmacology , percutaneous coronary intervention , radiology
Objective This study aimed to evaluate the effects of the combined use of external therapeutic ultrasound ( ETUS ) and the specific glycoprotein II b/ III a inhibitor tirofiban on myocardial no‐reflow in a canine model of acute myocardial infarction after reperfusion. Methods The canine myocardial no‐reflow model was established by a 3‐hour occlusion of the left anterior desecending coronary artery followed by a 2‐hour reperfusion. Twenty‐four canines were divided into four groups (6/group): (1) control, (2) tirofiban alone, (3) ETUS combined with tirofiban ( ETUS + tirofiban), and (4) ETUS alone. Results The area of no‐reflow in each of the three treatment groups was significantly decreased, compared with the control group, with the ETUS + tirofiban group having the smallest area. Also, the ETUS + tirofiban group had the highest recanalized rate of microvessels in the no‐reflow area and fewer impaired cellular organelles. The recovery rates of the endocardial and middle circumferential strain as well as longitudinal strain in the ETUS + tirofiban group were significantly greater than those of the tirofiban group. Moreover, the expression of hypoxia‐inducible factor‐1α ( HIF ‐1α) was significantly increased in the ETUS + tirofiban group, compared with the other groups. Conclusions The combined use of ETUS and tirofiban offers synergistic benefits for the treatment of myocardial no‐reflow.